Gerris Jan, Delvigne Annick, Dhont Nathalie, Vandekerckhove Frank, Madoc Bo, Buyle Magaly, Neyskens Julie, Deschepper Ellen, De Bacquer Dirk, Pil Lore, Annemans Lieven, Verpoest Willem, De Sutter Petra
Centre for Reproductive Medicine, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium
Centre for Reproductive Medicine, Clinique St Vincent, Rue Lefebvre 207, 4000 Rocourt (Liége), Belgium.
Hum Reprod. 2014 Sep;29(9):1941-8. doi: 10.1093/humrep/deu168. Epub 2014 Jul 3.
Does self-operated endovaginal telemonitoring (SOET) of the ovarian stimulation phase in IVF/ICSI produce similar laboratory, clinical, patient reported and health-economic results as traditional monitoring (non-SOET)?
SOET is not inferior to traditional monitoring (non-SOET).
Monitoring the follicular phase is needed to adapt gonadotrophin dose, detect threatening hyperstimulation and plan HCG administration. Currently, patients pay visits to care providers, entailing transportation costs and productivity loss. It stresses patients, partners, care providers and the environment. Patients living at great distance from centres have more difficult access to treatment. The logistics and stress during the follicular phase of assisted reproduction treatment (ART) is often an impediment for treatment.
STUDY DESIGNS, SIZE, DURATION: The study was a non-inferiority RCT between SOET and non-SOET performed between February 2012 and October 2013. Sample size calculations of number of metaphase II (MII) oocytes (the primary outcome): 81 patients were needed in each study arm for sufficient statistical power. Block randomization was used with allocation concealment through electronic files. The first sonogram was requested after 5 days of stimulation, after that mostly every 2 days and with a daily sonograms at the end.
PARTICIPANTS/MATERIALS, SETTINGS, METHODS: Inclusion criteria were age <41 years, undergoing ICSI, no poor response and having two ovaries. We used a small laptop with USB connected vaginal probe and developed a specific web site application. Sonographic training was given to all women at the initiation of a treatment attempt at the centre. The website contained demonstration material consisting of still images and video sequences, as well as written instructions regarding the use of the instrument and probe handling. In total, 185 eligible patients were recruited in four centres: 123 were randomized; 121 completed SOET (n = 59) or non-SOET (n = 62), and 62/185 (33%) eligible patients declined participation for various reasons.
Patient characteristics were comparable. The clinical results showed similar conception rates (P = 0.47) and ongoing pregnancy rates (SOET: 15/59 = 25%; non-SOET: 16/62 = 26%) (P = 1.00) were obtained. Similar numbers of follicles >15 mm diameter at oocyte retrieval (OR), ova at OR, MII oocytes, log2 MII oocytes, embryos available at transfer, top quality embryos and embryos frozen were obtained in the two groups, indicating non-inferiority of SOET monitoring. Regarding patient-reported outcomes, a significantly higher contentedness of patient and partner (P < 0.01), a higher feeling of empowerment, discretion and more active partner participation (P < 0.001) as well as a trend towards less stress (P = 0.06) were observed in the S versus the NS group. In the economic analysis, the use of SOET led to reduced productivity loss, lower transportation costs, and lower sonogram and consultation costs (all P < 0.001 but higher personnel cost than NS).
LIMITATIONS, REASONS FOR CAUTION: The study was stopped (no further funding) before full sample size was reached. There were also a few cases of unexpected poor response, leading to a wider SD than anticipated in the power calculation. However, although the study was underpowered for these reasons, non-inferiority of SOET versus non-SOET was demonstrated.
Home monitoring using SOET may provide a patient-centred alternative to the standard methods. ART sonograms can be made, and then sent to the care provider for analysis at any appropriate time and from anywhere if an internet connection is available. This approach offers several advantages for patients as well as care providers, including similar results to the traditional methods with less logistical stress and potentially bringing care to patients in poor resource settings.
STUDY FUNDING/COMPETING INTERESTS: Supported by an IOF (industrial research fund) of Ghent University (full protocol available at iBiTech) and as a demonstration project of Flanders Care (Flemish Government). There are no conflicts of interest to declare.
EC/2011/669 (Ghent University Hospital), B670201112232 (Belgian registration) and NCT01781143 (clinical trials number).
在体外受精/卵胞浆内单精子注射(IVF/ICSI)中,对卵巢刺激阶段进行自我操作的阴道远程监测(SOET),在实验室、临床、患者报告及卫生经济方面的结果是否与传统监测(非SOET)相似?
SOET并不劣于传统监测(非SOET)。
监测卵泡期对于调整促性腺激素剂量、检测潜在的过度刺激以及计划人绒毛膜促性腺激素(HCG)给药是必要的。目前,患者需要前往医疗服务提供者处就诊,这会产生交通成本和生产力损失。这给患者、伴侣、医疗服务提供者及环境都带来压力。居住在远离医疗中心地区的患者获得治疗更加困难。辅助生殖治疗(ART)卵泡期的后勤工作和压力常常阻碍治疗的进行。
研究设计、规模、持续时间:该研究是2012年2月至2013年10月期间在SOET和非SOET之间进行的非劣效性随机对照试验(RCT)。中期II(MII)卵母细胞数量(主要结局)的样本量计算:每个研究组需要81名患者以获得足够的统计效力。采用区组随机化,并通过电子文件进行分配隐藏。刺激5天后进行首次超声检查,之后大多每2天进行一次,最后每天进行超声检查。
参与者/材料、地点、方法:纳入标准为年龄<41岁、接受ICSI、无低反应且有两个卵巢。我们使用一台带有USB连接阴道探头的小型笔记本电脑,并开发了一个特定的网站应用程序。在中心开始治疗尝试时,对所有女性进行超声检查培训。该网站包含由静态图像和视频序列组成的演示材料,以及关于仪器使用和探头操作的书面说明。共有185名符合条件的患者在四个中心招募:123名被随机分组;121名完成了SOET(n = 59)或非SOET(n = 62),62/185(33%)符合条件的患者因各种原因拒绝参与。
患者特征具有可比性。临床结果显示受孕率相似(P = 0.47),持续妊娠率(SOET组:15/59 = 25%;非SOET组:16/62 = 26%)(P = 1.00)。两组在取卵时直径>15 mm的卵泡数量、取卵时的卵子数量、MII卵母细胞数量、log2 MII卵母细胞数量、移植时可用胚胎数量、优质胚胎数量及冷冻胚胎数量方面相似,表明SOET监测并不劣于非SOET监测。关于患者报告的结局,与非SOET组相比,SOET组患者和伴侣的满意度显著更高(P < 0.01),赋权感、自主权更高且伴侣参与度更积极(P < 0.001),以及压力有减轻趋势(P = 0.06)。在经济分析中,使用SOET导致生产力损失减少、交通成本降低、超声检查和咨询成本降低(均P < 0.001),但人员成本高于非SOET组。
局限性、谨慎理由:在达到完整样本量之前研究停止(无进一步资金)。也有一些意外的低反应病例,导致标准差比功效计算中预期的更宽。然而,尽管由于这些原因研究效力不足,但仍证明了SOET相对于非SOET的非劣效性。
使用SOET进行家庭监测可能为标准方法提供以患者为中心的替代方案。如果有互联网连接,可进行ART超声检查,然后在任何合适的时间和地点将其发送给医疗服务提供者进行分析。这种方法为患者和医疗服务提供者都提供了几个优势,包括与传统方法结果相似、后勤压力较小,并且有可能为资源匮乏地区的患者提供医疗服务。
研究资金/利益冲突:由根特大学的一项产业研究基金(IOF)(完整方案可在iBiTech获取)以及弗拉芒关怀(佛兰芒政府)的一个示范项目资助。无利益冲突声明。
EC/2011/669(根特大学医院)、B670201112232(比利时注册号)和NCT01781143(临床试验注册号)